| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) Emphysema due to alpha-1 antitrypsin deficiency (AATD) | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Respiratory System | |
Phase 3 topline data readout example | Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) Emphysema due to alpha-1 antitrypsin deficiency (AATD) | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Respiratory System | |
Phase 3 topline data readout example | Prolastin-C (Alpha1-Proteinase Inhibitor [Human] modified process) Emphysema due to alpha-1 antitrypsin deficiency (AATD) | Phase 3 | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Respiratory System |
Recent Updates
Recently added Catalysts
Grifols, S.A.
$7.68
+0.03 (+0.38%)
B 60Pipeline Score Undervalued Pharma · Commercial
Market Cap
2.01 B
EPS
0.71
P/E Ratio
10.86 $
Value Trade
2.20 M
-1.6 %
Week
-3.22 %
1 Month
0.46 %
3 Month
-1.73 %
6 Month
-56.7 %
5 Year
18.97 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
356.65 K
52 Week Range
6.96 - 10.23
% held by Insiders
0.06 %
% held by Institutions
56.45 %
Enterprise Value
19.80 B
Total Shares
261.43 M
Short %
1.32 %
Float Shares
258.08 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Grifols, S.A.
11Total events
3Upcoming
3Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseGAMMAKEDCorporate
Subscribe to view catalyst details
TBD
●Last Patient Last VisitProlastin-CTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B60
Pipeline Score $7.2B
Pipeline ValueUndervalued
Valuation Signal35
Drugs Scored3.5x
rNPV / MCap Top 90%
Small Cap (rank 95 of 938)
Percentile RankGrifols, S.A. holds a solid B-grade pipeline (60/100), with $12.6B risk-adjusted pipeline value, led by Convalescent anti-SARS-CoV-2 MBT plasma in SARS-CoV-2 Infection (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convalescent anti-SARS-CoV-2 MBT plasma Monoclonal antibody | SARS-CoV-2 Infection | Phase 2 | NCT04621123 | 54% | $2.5B | COMPLETED | 384 | - | - | Jul 28, 2021 | - | Sep 8, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GRFS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GRFS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GRFSKedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED®
Kedrion Biopharma has announced an extension of its agreement with Grifols to continue marketing GAMMAKED®, an intravenous immunoglobulin therapy, in the U.S. This extension aims to ensure reliable access for patients suffering from primary immunodeficiency, ITP, and CIDP. The collaboration reflects a commitment to maintaining treatment continuity and supporting patients with chronic conditions.
Read more →GRFSGrifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols has announced the completion of the clinical portion of its SPARTA Phase 3 trial, which evaluates the efficacy and safety of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency. The trial involved 345 participants across 37 sites in 16 countries. Topline results are anticipated by the end of 2026, marking a significant advancement in treatment options for this underdiagnosed condition.
Read more →GRFSFOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
FOXO Technologies Inc.'s subsidiary, Vector BioSource, has entered a definitive agreement to acquire four blood collection centers from Grifols Bio Supplies. This acquisition aims to enhance Vector's biospecimen sourcing capabilities and is expected to generate over $10 million in net revenues within the first year. The deal is contingent on obtaining necessary FDA licensure and regulatory approvals, with closing anticipated in late 2026.
Read more →GRFSGrifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has commenced two Phase 3 clinical trials, SIGMA and XPERT, to expand the indications for its immunoglobulin products, GAMUNEX-C and XEMBIFY. The SIGMA trial will assess GAMUNEX-C's effectiveness in patients with secondary immunodeficiency, while XPERT will compare XEMBIFY's profile against GAMUNEX-C for treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy. These trials aim to enhance treatment options for patients with immune disorders.
Read more →GRFSREPEAT - Grifols deaths and harm: Patient safety & options for accountability
A press conference will address patient safety issues related to Grifols, a major plasma-derived product manufacturer. The event will cover reported adverse events, patients' legal rights, and regulatory oversight. Concerns have been raised about Grifols' practices, including the deaths of two patients and ongoing compliance issues despite Health Canada's approval.
Read more →GRFSGrifols deaths and harm: Patient safety & options for accountability
A press conference will address patient safety concerns regarding Grifols, a major plasma product manufacturer. The event will highlight reported adverse events, legal rights of patients, and the need for regulatory accountability. Despite serious compliance issues, Grifols continues to operate in Canada under a monopoly contract. The discussion aims to enhance public confidence in blood and plasma systems.
Read more →GRFSGrifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols has launched FESILTY, a new fibrinogen concentrate, in the U.S. for treating acute bleeding episodes in patients with congenital fibrinogen deficiency. Approved by the FDA, FESILTY enhances treatment options for healthcare professionals and patients. It is designed for rapid reconstitution and effective management of bleeding, although it carries some risks, including hypersensitivity reactions and thrombotic events.
Read more →GRFSGrifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
Grifols has presented findings from its Chronos-PD program, revealing that biological changes linked to Parkinson's disease can occur up to 12 years before clinical diagnosis. This groundbreaking research, showcased at the AD/PD 2026 conference, utilizes advanced proteomics and AI to identify early biomarkers, potentially enhancing early detection and treatment strategies. The study analyzed over 2,600 plasma samples, confirming existing biomarkers and discovering new ones.
Read more →GRFSexv99w1 GRIFOLS TO ACQUIRE TALECRIS BIOTHERAPEUTICS CREATING A WORLD LEADING PROVIDER OF LIFE-SAVING PLASMA PROTEIN THERAPIES The combination of Grifols and Talecris will create a diversified, global provider of life-sav
GRIFOLS TO ACQUIRE TALECRIS BIOTHERAPEUTICS CREATING A WORLD LEADING PROVIDER OF LIFE-SAVING PLASMA PROTEIN THERAPIES The combination of Grifols and Talecris will create a diversified, global provider of life-saving and life enhancing plasma protein therapeutics built on the
Read more →Competitive Position
How GRFS ranks across every disease it competes inCompetitive Position is a premium feature
See how GRFS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial